Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Claus Riemer

Alexander Flohr

Roger David Norcross

Matthias Heinrich Nettekoven

Hasane Ratni

Roland Jakob-Roetne

Henner Knust

Sabine Kolczewski

Anja Limberg

Lucinda Steward

Juergen Wichmann

Thomas Johannes Woltering

Philippe Jablonski

Thierry Godel

Olivier Roche

Walter Vifian

Michael Bos

Alexander Alanine

Andrew Sleight

Aubry Kern Miller

Caterina Bissantz

Andreas Koblet

Kenichi Kawasaki

Walter Hunkeler

Theodor Stoll

Xihan Wu

Daniela Brunner

Eric Prinssen

Angelique Patiny-Adam

Bavani G Shankar

Jessica Malberg

Deborah Hartman

Hans Hilpert

Jens-Uwe Peters

Luca Claudio Gobbi

Heinz Stadler

Rene Wyler

Marius Hoener

Marie-Paule Heitz Neidhart

Markus Boehringer

Michael B&ouml;s

Bernd Michael Loeffler

Bernd Buttelmann

Sonia Maria Poli

Peter Weiss

Gerda Huber Trottmann

Will Spooren

Jean-Luc Moreau

Gavin John Kilpatrick

Norcross David Roger

Laurence Gross

Sonia Poli

Angélique Patiny-Adam

The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar, X, X, R, R, R, m, n and the dotted line are as defined herein which compounds are useful for treating certain central nervous system disorders as described herein.

Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives

The present application relates to compounds of formula wherein R, R, R, R, and n are defined hereinor to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidine compounds

The present invention relates to compounds of formula wherein R, R, R, R, Z, and n are as defined hereinor to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidine derivatives

The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula wherein is phenyl or a heteroaryl group, selected from pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl or pyrazolyl; is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be on all free positions;

2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders

The present invention relates to compounds of formula I wherein R, R, R, Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.

Pyrrolidine derivatives as NK2 receptor antagonists

The present invention relates to 2-aminoquinolines of formula I wherein R, Rand Rare as defined in the specification, as 5-HTreceptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of CNS disorders.

Quinolines

The present invention relates to a compounds of formula I wherein R, R, Ar, Ar, R', R&#x2033;, m, n, and o are defined in the specification or to a pharmaceutically active salt, racemic mixture, enantiomer, optical isomer or to tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidines as NK3 receptor antagonists

The present invention is concerned with 2-aminoquinoline derivatives of formula I wherein Rand Rare as described herein and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them, and methods for their manufacture. These compounds are 5-HTreceptor antagonists, useful for the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders or gastrointestinal disorders.

2-aminoquinolines

The present application relates to compounds of formula wherein the definitions are as described herein. The present compounds are high potential NK-3 receptor antagonists that are useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Piperidine derivatives as NK3 receptor antagonists

The present invention relates to a compounds of formula I 

The present invention relates to a compounds of formula I wherein A, Ar, R, R2, R3, R4, p, and o are as defined in the specification and claims or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, bipolar disorders, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidine derivatives as NK3 receptor antagonists

The present invention relates to a compounds of formula I wherein

Quinazoline derivatives as NK3 receptor antagonists

The present invention relates to a compound of formula I wherein

Pyrrolidine derivatives as NK-3 receptor antagonists

The present invention relates to compounds of formula (I) wherein A, R, R, R, R, and Rare as described herein, pharmaceutical compositions containing them, and methods for their manufacture. These compounds are 5-HTreceptor antagonists and are useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders or gastrointestinal disorders.

The present invention is concerned with 2-aminoquinoline derivatives of formula I where R, R, R, R, R, R, A, and n are as defined in the specification and claims, their use 5-HTreceptor antagonists, their manufacture, and pharmaceutical compositions containing them.

Growing community of inventors

Freiburg, Germany

Claus Riemer